ICER panel: Low value for Vertex CF drugs

The Midwest Comparative Effectiveness Public Advisory Council (CEPAC) voted that the long-term value was low for three cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as some patients and payers voiced their frustration at the biotech's pricing of the therapies.

The 12-member CEPAC panel, which is an affiliate of the Institute for Clinical and Economic Review (ICER), reviewed Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Symdeko tezacaftor/ivacaftor. In all three

Read the full 672 word article

User Sign In